Search

Your search keyword '"Qin, Shukui"' showing total 11 results
Start Over Author "Qin, Shukui" Journal journal of hepatology
11 results on '"Qin, Shukui"'

1. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

Author

Kudo, Masatoshi, Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii, Vogel, Arndt, Tovoli, Francesco, Ueshima, Kazuomi, Aikata, Hiroshi, López, Carlos López, Pracht, Marc, Meng, Zhiqiang, Daniele, Bruno, Park, Joong-Won, Palmer, Daniel, Tamai, Toshiyuki, Saito, Kenichi, Dutcus, Corina E., and Lencioni, Riccardo

Published
2023
Full Text
View/download PDF

3. GS-005 mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma

Author

Sangro, Bruno, primary, Kudo, Masatoshi, additional, Erinjeri, Joseph, additional, Qin, Shukui, additional, Ren, Zhenggang, additional, Chan, Stephen, additional, Arai, Yasuaki, additional, Heo, Jeong, additional, Mai, Ahn, additional, Escobar, Jose, additional, Chuken, Yamil Alonso Lopez, additional, Yoon, Jung-Hwan, additional, Tak, Won Young, additional, Suttichaimongkol, Tanita, additional, Bouattour, Mohamed, additional, Lin, Shi-Ming, additional, Żotkiewicz, Magdalena, additional, Ali, Sajid, additional, Cohen, Gordon, additional, and Lencioni, Riccardo, additional

Published
2024
Full Text
View/download PDF

4. Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the RATIONALE-301 study

Author

Meyer, Tim, primary, Finn, Richard S., additional, Kudo, Masatoshi, additional, Zhu, Andrew X., additional, Li, Songzi, additional, Chen, Yaxi, additional, Boisserie, Frederic, additional, Abdrashitov, Ramil, additional, Vogel, Arndt, additional, and Qin, Shukui, additional

Published
2023
Full Text
View/download PDF

5. Impact of baseline liver function on overall survival (OS) and safety in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS): results from the RATIONALE-301 study

Author

Kudo, Masatoshi, primary, Vogel, Arndt, additional, Meyer, Tim, additional, Boisserie, Frederic, additional, Li, Songzi, additional, Abdrashitov, Ramil, additional, Chen, Yaxi, additional, Zhu, Andrew X., additional, Qin, Shukui, additional, and Finn, Richard S., additional

Published
2023
Full Text
View/download PDF

6. IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

Author

Kaseb, Ahmed, primary, Chen, Minshan, additional, Chow, Pierce, additional, Kudo, Masatoshi, additional, Lee, Han Chu, additional, Yopp, Adam, additional, Becker, Lars, additional, Hernandez, Sairy, additional, Kovic, Bruno, additional, Lian, Qinshu, additional, Ma, Ning, additional, Wu, Chun, additional, Qin, Shukui, additional, and Cheng, Ann-Lii, additional

Published
2023
Full Text
View/download PDF

9. GS-011 - IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation

Author

Kaseb, Ahmed, Chen, Minshan, Chow, Pierce, Kudo, Masatoshi, Lee, Han Chu, Yopp, Adam, Becker, Lars, Hernandez, Sairy, Kovic, Bruno, Lian, Qinshu, Ma, Ning, Wu, Chun, Qin, Shukui, and Cheng, Ann-Lii

Published
2023
Full Text
View/download PDF

10. Atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study

Author

Ducreux, Michel, primary, Zhu, Andrew, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Kim, Tae-You, additional, Lim, Ho Yeong, additional, Kudo, Masatoshi, additional, Breder, Valeriy, additional, Merle, Philippe, additional, Kaseb, Ahmed, additional, Li, Daneng, additional, Verret, Wendy, additional, Xu, Zhen, additional, Hernandez, Sairy, additional, Liu, Juan, additional, Shao, Hui, additional, Huang, Chen, additional, Cheng, Ann-LII, additional, Finn, Richard, additional, and Galle, Peter, additional

Published
2020
Full Text
View/download PDF

11. LBO10 - Atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study

Author

Ducreux, Michel, Zhu, Andrew, Qin, Shukui, Ikeda, Masafumi, Kim, Tae-You, Lim, Ho Yeong, Kudo, Masatoshi, Breder, Valeriy, Merle, Philippe, Kaseb, Ahmed, Li, Daneng, Verret, Wendy, Xu, Zhen, Hernandez, Sairy, Liu, Juan, Shao, Hui, Huang, Chen, Cheng, Ann-LII, Finn, Richard, and Galle, Peter

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results